We hypothesize the reduced efficacy of belimumab observed in some SLE patients may be due to ACAAs binding to BAFF close to the epitope recognized by the monoclonal antibody, thereby neutralizing or impairing its action. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.